Patients with neuroendocrine tumours who may have a much longer life expectancy than those with aggressive tumours report placing a higher priority on QoL factors, such as remaining independent, compared with longer survival as a primary treatment goal. However, they often feel that their clinicians do not share their priorities, shows...
Some patients with neuroendocrine tumours prefer quality over longevity
Deepa Koli | Clinical Summary | 03 January 2023
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.Create a Free Account I have an account